Startup Conference London 2016, May 18, London, United Kingdom

Director Daniel Daugaard, Trifork eHealth

Director Daniel Daugaard

Biography: Director Daniel Daugaard

Daniel Gewecke Daugaard M.Sc. in Economics and Business Administration, Management of Innovation and Business Development. Daniel is the Director of Trifork eHealth. He comes from a background in entrepreneurship and from the pharmaceutical industry, working with innovation and patient centric services. He has a natural aptitude for strategy and innovation within digital health. Daniel was Co-Founder of 1calendar.com, a web and mobile calendar application for educational institutions and students. In April 2011, 1Calendar became an official Google Chrome International launch partner. The marketing campaign was arranged in cooperation with Google’s Chrome Web team and gained 15.000 downloads in a couple of months from Chrome users internationally.

Presentation: Trifork eHealth. Medical adherence and M-Boks

Track: Start-up pitches / Time: Wednesday 12:00 - 12:10 / Location: To be announced

Trifork eHealth is a medical-tech spin-off specialised in digital health and devoted to fighting the global health challenges. The company is establishing close cooperation with some of the leading players in the pharmaceutical, biotechnical and medical device industry to develop solutions that fundamentally changes the lives of people with chronic diseases. In this talk Daniel, Director of Trifork eHealth, will talk about medication adherence and M-Boks (mobile medical application). Approximately 50% of the worlds population have bad medication adherence. They forget to take their medicine, refuse to take their medicine or fail to take their medicine correctly. Bad medication adherence is a global healthcare issue that leads to accelerated disease progression, early mortality and huge economic expenses for society. M-Boks is a mobile medical application that automatically keeps track of all prescription medicine, reminds the user to take the medicine and guides the user on appropriate usage. The solution is being developed in cooperation with Big Pharma, leading hospitals and national Biobanks. The worlds largest clinical trial on a mobile medical device is expected to document the effectiveness of m-Boks over a two-year period.